Madrigal Pharmaceuticals, Inc. (MDGL)
- Previous Close
222.26 - Open
221.85 - Bid 211.68 x 100
- Ask 212.73 x 200
- Day's Range
206.03 - 224.68 - 52 Week Range
119.76 - 322.67 - Volume
620,067 - Avg. Volume
569,258 - Market Cap (intraday)
4.447B - Beta (5Y Monthly) -0.44
- PE Ratio (TTM)
-- - EPS (TTM)
-19.99 - Earnings Date May 7, 2024 - May 13, 2024
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
394.54
Madrigal Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development of therapeutics for the treatment of non-alcoholic steatohepatitis (NASH) in the United States. Its lead product candidate is resmetirom, a liver-directed thyroid hormone receptor beta agonist, which is in Phase 3 clinical trials for treating NASH. The company is headquartered in West Conshohocken, Pennsylvania.
www.madrigalpharma.comRecent News: MDGL
Performance Overview: MDGL
Trailing total returns as of 4/19/2024, which may include dividends or other distributions. Benchmark is .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: MDGL
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: MDGL
Valuation Measures
Market Cap
4.67B
Enterprise Value
4.15B
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
--
Price/Book (mrq)
11.52
Enterprise Value/Revenue
--
Enterprise Value/EBITDA
-11.52
Financial Highlights
Profitability and Income Statement
Profit Margin
0.00%
Return on Assets (ttm)
-47.41%
Return on Equity (ttm)
-123.98%
Revenue (ttm)
--
Net Income Avi to Common (ttm)
-373.63M
Diluted EPS (ttm)
-19.99
Balance Sheet and Cash Flow
Total Cash (mrq)
634.13M
Total Debt/Equity (mrq)
28.91%
Levered Free Cash Flow (ttm)
-192.38M
Research Analysis: MDGL
Analyst Price Targets
Fair Value
Analyst Recommendations
- Strong Buy
- Buy
- Hold
- Underperform
- Sell